Exelixis Inc Proceeds from (Payments for) Other Financing Activities
Exelixis Inc (EXEL) reported Proceeds from (Payments for) Other Financing Activities of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-18.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromPaymentsForOtherFinancingActivities · last filed 2022-02-18
- Exelixis Inc proceeds from (payments for) other financing activities for the quarter ending 2021-01-01 was $0.00.
- Exelixis Inc proceeds from (payments for) other financing activities for the quarter ending 2020-10-02 was $0.00.
- Exelixis Inc proceeds from (payments for) other financing activities for the quarter ending 2020-07-03 was $0.00.
- Exelixis Inc proceeds from (payments for) other financing activities for the quarter ending 2020-04-03 was $0.00.
- Exelixis Inc proceeds from (payments for) other financing activities for fiscal 2021 was $0.00.
- Exelixis Inc proceeds from (payments for) other financing activities for fiscal 2021 was $0.00.
- Exelixis Inc proceeds from (payments for) other financing activities for fiscal 2020 was -$42.00K.
- Exelixis Inc proceeds from (payments for) other financing activities for fiscal 2018 was -$13.00K.
| Period end | Proceeds from (Payments for) Other Financing Activities 3 month | Proceeds from (Payments for) Other Financing Activities 6 month | Proceeds from (Payments for) Other Financing Activities 9 month | Proceeds from (Payments for) Other Financing Activities 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-02-18 | |||
| 2021-01-01 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | $0.00 derived: sum of 2 quarters · filed 2022-02-18 | $0.00 derived: sum of 3 quarters · filed 2022-02-18 | $0.00 10-K · filed 2022-02-18 |
| 2020-10-02 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $0.00 derived: sum of 2 quarters · filed 2020-11-05 | $0.00 10-Q · filed 2020-11-05 | -$8.00K derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-07-03 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $0.00 10-Q · filed 2020-08-06 | -$8.00K derived: sum of 3 quarters · filed 2022-02-18 | -$20.00K derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-04-03 | $0.00 10-Q · filed 2020-05-05 | -$8.00K derived: sum of 2 quarters · filed 2022-02-18 | -$20.00K derived: sum of 3 quarters · filed 2022-02-18 | -$31.00K derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-01-03 | -$8.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | -$20.00K derived: sum of 2 quarters · filed 2022-02-18 | -$31.00K derived: sum of 3 quarters · filed 2022-02-18 | -$42.00K 10-K · filed 2022-02-18 |
| 2019-09-27 | -$12.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$23.00K derived: sum of 2 quarters · filed 2020-11-05 | -$34.00K 10-Q · filed 2020-11-05 | |
| 2019-06-28 | -$11.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$22.00K 10-Q · filed 2020-08-06 | ||
| 2019-03-29 | -$11.00K 10-Q · filed 2020-05-05 | |||
| 2018-12-28 | -$13.00K 10-K · filed 2021-02-11 | |||
| 2017-12-29 | $0.00 10-K · filed 2020-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |